GlassScriptPhysician profile
Bernard T Sy
NPI 1174669998
$16,635.68
in general payments reported to CMS, 2019-2025
59 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,563 · 2020: $1,986 · 2021: $2,524 · 2022: $2,710 · 2023: $2,496 · 2024: $3,110 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,852.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,707.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,941.56 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,778.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,190.41 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,112.84 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $1,004.48 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $755.16 | 2019-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $698.02 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $464.43 | 2021-2025 | |
| Pfizer INC. | $388.95 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $334.97 | 2020-2023 | |
| Xeris Pharmaceuticals, INC. | $331.29 | 2021-2024 | Gvoke Hypopen, Keveyis |
| Sanofi-Aventis U.S. LLC | $243.93 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $236.24 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $224.04 | 2019-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Sy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.